News Formal

Morgan Stanley warns snack companies that weight loss drug study showed 'significant reduction in food consumption'

  • 📰 CNBC
  • ⏱ Reading Time:
  • 24 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 72%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

The firm said it may not be a near-term risk as drug usage still has to ramp up.

The use of Eli Lilly 's Mounjaro for weight loss can pull shoppers away from the snack aisle — though the transition will likely be gradual, according to Morgan Stanley. Mounjaro belongs to a class of drugs gaining popularity for their weight-loss capabilities. While its growth has been stymied by hurdles to off-label use, Mounjaro should see Food and Drug Administration approval to treat obesity by the end of 2023, analyst Pamela Kaufman said.

are likely to be most impacted by growing adoption of anti-obesity drugs, but believe the impact will be modest in the near-term as adoption is expect to increase gradually." Mounjaro patients cut calorie intake at lunch by 71%, according to the study. More specifically, those taking the medication reduced intake to 268 calories at week six from 955 at the start, while those taking the placebo increased their lunchtime calories over the course of the study.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 12. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Morgan Stanley's Wilson: Next rally attempt will fail as investors are punishing earnings reports.Critical information for the U.S. trading day
ソース: MarketWatch - 🏆 3. / 97 続きを読む »